Mon. March 22, 2010
-
Reuters
March 22, 2010
VX) Genentech unit and other biological drugmakers won a 12-year period of exclusive sales for brand-name drugs before facing competition from generic ...
PR-CANADA.net (press release)
March 22, 2010
Actemra (tocilizumab), marketed by Roche-
Genentech, is the first
IL-6 receptor inhibitor agent approved for rheumatoid arthritis. ...
San Francisco Chronicle (blog)
March 22, 2010
As researchers, sneakers on, trickled out of UC
San Francisco's
Genentech Hall on a warm, windless evening this week, assorted persons with ...
News-Medical.net
March 19, 2010
Actemra (tocilizumab), marketed by Roche-
Genentech, is the first
IL-6 receptor inhibitor agent approved for rheumatoid arthritis. ...
FierceBiotech
March 19, 2010
@FierceBiotech: Roche/Genentech try to develop companion diagnostic tests for all their experimental drugs. | Follow @FierceBiotech @JohnCFierce: I'm ...
BusinessWeek
March 19, 2010
It receives most of its revenue from the lung and pancreatic
cancer drug Tarceva, which it sells in partnership with
Genentech, which is now part of Roche. ...
Trading Markets (press release)
March 19, 2010
Research and
markets (http://www.researchandmarkets.com/research/dea82c/
Genentech_compan) has announced the addition of the "
Genentech - Company PicShot" ...
FierceBiotech
March 19, 2010
Yesterday, Roche concluded its first
pipeline update following last year's acquisition of
Genentech. As expected, the Swiss drugmaker highlighted its ...
BusinessWeek
March 19, 2010
Genentech Inc. spent $610000 lobbying the federal government in the fourth quarter, according to a recent disclosure form. The company, now part of Swiss ...
PR Newswire (press release)
March 18, 2010
Actemra (tocilizumab), marketed by Roche-
Genentech, is the first
IL-6 receptor inhibitor agent approved for rheumatoid arthritis. ...
Trading Markets (press release)
March 18, 2010
Genentech, a wholly-owned member of the Roche Group, has submitted a supplemental biologics license application, or sBLA, to the FDA for Actemra for the ...
MarketWatch (press release)
March 18, 2010
The most advanced compound, trastuzumab-DM1 (T-DM1), is in Phase III testing being conducted by Genentech and Roche. Other ImmunoGen collaborative partners ...
San Francisco Business Times
March 18, 2010
Genentech Inc.'s early drug research unit hired former Cytokinetics Inc. founder,
CEO and chairman Dr. James Sabry as vice president of partnering. ...
Reuters
March 16, 2010
VX) first product review since its
Genentech buyout will reassure
markets about its
pipeline strength and justify its premium rating, after a series of ...
MarketWatch (press release)
March 16, 2010
Founded more than 30 years ago,
Genentech is a leading
Biotechnology company that discovers, develops, manufactures and commercializes medicines to treat ...
HemOncToday
March 15, 2010
Patients were assigned to weekly 375 mg/m 2 IV rituximab (Rituxan, Genentech) for 28 days plus 40 mg oral dexamethasone (n=49) or 40 mg oral dexamethasone ...
FiercePharma
March 15, 2010
Some months into its full ownership of
Genentech, Roche has seen a couple of setbacks in its development program for that "
pipeline-in-a-drug," Avastin. ...
PR Newswire (press release)
March 15, 2010
Among his many achievements during his time with Roche, he had significant involvement in the acquisition and privatisation of Genentech, he led the ...
Mountain View Voice
March 13, 2010
What I think would be a bad idea is what is happening with
Genentech and the City of South
San Francisco. As much
money as they injected into the City over ...
The IN VIVO Blog (blog)
March 13, 2010
For example, Frank engineered the 1995 and 1999
extensions of the epic Roche-
Genentech relationship. His ties to
Genentech were so strong that, ...
PR-CANADA.net (press release)
March 12, 2010
... Roche/Genentech/ Chugai's Herceptin as an add-on to standard chemotherapy earns Decision Resources' proprietary clinical gold standard status in 2013, ...
Oregon Business
March 12, 2010
... leading the fight to protect farmland from development as major companies such as
Intel,
Genentech and SolarWorld expand on formerly rural properties. ...
Drug Store News
March 12, 2010
On the same day it announced the Sutent results,
Pfizer also halted a phase 3 study of
Genentech's and OSI Pharmaceuticals' Tarceva (erlotinib) combined ...
Drug Store News
March 12, 2010
BusinessWeek
March 12, 2010
ZymoGenetics said he has also worked with Genentech, which is now a division of Swiss drugmaker Roche. ZymoGenetics said Sorensen resigned from its board, ...
Drug Store News
March 12, 2010
12) A late-stage clinical trial of a
Genentech drug for men with late-stage prostate
cancer has failed, the biotech company announced
friday. ...
Pharmaceutical Technology Magazine (blog)
March 11, 2010
And this doesn't include layoffs from the merger of Roche and
Genentech, nor the 860 jobs that were announced at
Boehringer Ingelheim in August. ...
ETF Database
March 10, 2010
In this specific case, Genentech, a major component of BBH, was acquired by Roche Holding AG. Genentech was deleted from the index underlying and the cash ...
MarketWatch (press release)
March 10, 2010
GDC-0449 is currently being developed in Phase II clinical trials by Curis' collaborator Genentech, including in a pivotal Phase II trial in advanced basal ...
MedPage Today
March 10, 2010
No dose-limiting toxicity occurred, Ivor Caro, MD, of
Genentech in South
San Francisco, Calif., and colleagues reported in a poster presentation here at the ...
BusinessWeek
March 10, 2010
Google's business customers include
Genentech Inc. and the city of Orlando,
Florida.
Google rose $5.11 to $565.30 at 9:49 am New York time in
Nasdaq Stock ...
Courthouse News Service
March 9, 2010
Xoma and Genentech, the manufacturers of Raptiva, knew the risks associated with continuous immunosuppressive therapy but repeatedly denied the need for ...
Genetic Engineering News (press release)
March 9, 2010
On March 3,
Genentech submitted an IND for one such compound that was developed using Seattle
genetics' ADC
technology under their collaboration. ...
SFist
March 9, 2010
Via TN: "will now always look both ways before crossing the street because you never know when af*cking giant Genentech commuter bus will run the red light ...
MarketWatch (press release)
March 9, 2010
... Bristol-Myers Squibb Company and the conclusion of various collaboration agreements with
GlaxoSmithKline, Bristol-Myers Squibb Company and
Genentech. ...
Cancer Consultants
March 8, 2010
Initial results of this Phase III clinical trial were made available in a press release from Genentech; full results will be presented at a future medical ...
MarketWatch (press release)
March 8, 2010
The most advanced compound, trastuzumab-DM1 (T-DM1), is in Phase III testing being conducted by Genentech and Roche. Other ImmunoGen collaborative partners ...
Boston Globe
March 8, 2010
The companies' partnership was originally struck in the mid-1990s by
California biotechs
Genentech Inc. and Idec Pharmaceuticals Corp., which developed ...
Reuters
March 8, 2010
[ID:nGEE5BA04M] Ocrelizumab, developed by Roche's
Genentech unit and Biogen, is similar to Rituxan, which is already approved to treat
cancer and rheumatoid ...
